J. Scott Garland
Director · Enliven Therapeutics, Inc.
IndividualSelling only
- 2025
- Oct 5, 2026
- 9
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies J. Scott Garland files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
- Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
- Helen Louise Collins - $5.39M in ELVN purchases and sales in the last 12 months
- Joseph P. Lyssikatos - $4.71M in ELVN purchases and sales in the last 12 months
- Benjamin Hohl - $1.53M in ELVN purchases and sales in the last 12 months
- Anish Patel - $1.47M in ELVN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is J. Scott Garland?
J. Scott Garland is a corporate insider, tracked as Director of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has J. Scott Garland submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has J. Scott Garland been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($607K) across all tracked filings.
